Success Metrics

Clinical Success Rate
96.4%

Based on 163 completed trials

Completion Rate
96%(163/169)
Active Trials
8(4%)
Results Posted
14%(23 trials)
Terminated
6(3%)

Phase Distribution

Ph phase_4
17
8%
Ph phase_3
12
6%
Ph early_phase_1
6
3%
Ph phase_1
56
27%
Ph phase_2
12
6%
Ph not_applicable
101
49%

Phase Distribution

62

Early Stage

12

Mid Stage

29

Late Stage

Phase Distribution204 total trials
Early Phase 1First-in-human
6(2.9%)
Phase 1Safety & dosage
56(27.5%)
Phase 2Efficacy & side effects
12(5.9%)
Phase 3Large-scale testing
12(5.9%)
Phase 4Post-market surveillance
17(8.3%)
N/ANon-phased studies
101(49.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.1%

163 of 177 finished

Non-Completion Rate

7.9%

14 ended early

Currently Active

8

trials recruiting

Total Trials

208

all time

Status Distribution
Active(13)
Completed(163)
Terminated(14)
Other(18)

Detailed Status

Completed163
unknown17
Withdrawn8
Terminated6
Active, not recruiting4
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
208
Active
8
Success Rate
96.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (2.9%)
Phase 156 (27.5%)
Phase 212 (5.9%)
Phase 312 (5.9%)
Phase 417 (8.3%)
N/A101 (49.5%)

Trials by Status

active_not_recruiting42%
unknown178%
enrolling_by_invitation10%
terminated63%
recruiting42%
withdrawn84%
completed16378%
suspended10%
not_yet_recruiting42%

Recent Activity

Clinical Trials (208)

Showing 20 of 208 trialsScroll for more
NCT07604519Not Applicable

Multi-Ingredient Supplementation in Professional Football Players

Not Yet Recruiting
NCT07305935Not Applicable

Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury

Completed
NCT06610110Not Applicable

Caffeine, CYPA12 and Resistance Exercise

Completed
NCT07238465Phase 3

Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome

Recruiting
NCT07412951Not Applicable

Effects of Caffeine and Shot Put Performance

Completed
NCT06686628Phase 1

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Completed
NCT04570085Phase 3

Effect of CAFfeine on Cognition in Alzheimer's Disease

Recruiting
NCT07530185Not Applicable

Effects of L-Tyrosine and Caffeine on Performance in Elite Boxers

Not Yet Recruiting
NCT07520864Not Applicable

Effects of Caffeine on Elite Weightlifting Performance

Completed
NCT00961792Not Applicable

Chicago Social Drinking Project

Active Not Recruiting
NCT07501806Not Applicable

Effect of the Combination of Nitrate and Caffeine on Critical Power In Trained Male Cyclists

Completed
NCT07479875Not Applicable

Caffeine Supplementation and Strength Endurance in Brazilian Jiu-jitsu Athletes

Completed
NCT05325502Not Applicable

Does Caffeine Facilitate Human Reward Learning Behaviors?

Active Not Recruiting
NCT07466732Early Phase 1

Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males

Enrolling By Invitation
NCT06564441Phase 1

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Completed
NCT07466654Not Applicable

Low-Dose Caffeine and Taurine Effects on Performance

Completed
NCT07456670Phase 2

Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support

Not Yet Recruiting
NCT07458594Not Applicable

Combined Caffeine and Rhodiola Rosea on Aerial Duel Performance in Soccer

Completed
NCT04886869Not Applicable

Caffeine and the Autonomic Nervous System

Completed
NCT06145490Not Applicable

Neurobehavioral Correlates of Caffeine on Anxiety, Avoidance and Interoception in Healthy Individuals and Panic Disorder.

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
208